DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions

Information source: Par Pharmaceutical, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: To Determine Bioequivalence Under Fasting Conditions

Intervention: Dronabinol (Drug); Marinol (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Par Pharmaceutical, Inc.

Official(s) and/or principal investigator(s):
Dilip K Guha-Ray, M.D., Principal Investigator, Affiliation: BASi Baltimore Clinical Research Unit

Summary

The purpose of this study is to compare the rate and extent of absorption of Dronabinol 10 mg capsules verses Marinol.

Clinical Details

Official title: A Comparative Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label

Primary outcome: Bioequivalence

Detailed description: To compare the plasma levels of dronabinol (delta-9-tetrahydrocannabinol)and the principle active metabolite 11-OH-delta-9-tetrahydrocannabinol levels produced after administration of the test formulation with those produced after administration of a marketed reference product, under fasted conditions.

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Healthy volunteers, 18 - 55 years of age

- Subjects must be within 18 to 29. 9 kilograms/m2 per the BMI

- General good health as determined by medical history and physical examination within

30 days prior to the start of the study

- Blood chemistry, hematology, and urinalysis tests will be performed within 30 days

prior to the start of the study

- No participation in an investigational drug study or donation of blood within 30 days

prior to the start of the study

- At screening, subjects must have blood pressure and pulse rate within specified

ranges

- No grapefruit juice or grapefruit-containing products for at least 72 hours prior to

drug administration, each period. Subjects will be queried at check-in each period on consumption of grapefruit juice or grapefruit containing products. Results will be recorded and reported in the final report.

- No alcohol consumption for at least 24 hours prior to drug administration, each

period

- No caffeine or xanthine consumption for 48 hours prior prior to drug administration,

each period

- No prescription drugs (excluding hormonal contraceptives) within 14 days prior to

drug administration, each period

- Subjects should refrain from taking OTC preparations, and/or nutritional supplements

within 7 days prior to drug administration, each period. Subjects shall refrain from taking herbal remedies within 14 day prior to drug administration, and throughout the study periods

- Female subjects must not be pregnant or nursing; and must be surgically sterile; one

year post-menopausal; or on hormonal contraceptive agents), a diaphragm or condom with spermicidal foam or jelly, or IUD for at least 3 months prior to drug administration and agree to use the same method of contraception for at least 1 month after the last drug administration

- Negative serum pregnancy test at screening and negative urine pregnancy test prior to

drug administration, each period

- Negative HIV 1, hepatitis B surface antigen, an urine screen for drugs of abuse

within 30 days prior to the start of the study Exclusion Criteria:

- Disease or condition that could impact interpretation of study results or a condition

which treatment would be contraindicated per currently approved product labeling

- Subjects had any of the following conditions:

- used any prescription or OTC medication within 14 days of study initiation

- a positive urine test for illicit drugs

- participated in a clinical investigation within the past 30 days

- had clinically significant allergies to drugs or foods, ot

- any condition that might place them at increased risk of complications

Locations and Contacts

BASi, Baltimore, Maryland 21201, United States
Additional Information

Starting date: January 2006
Last updated: June 22, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017